When combining these agents, patients may experience additive gastrointestinal effects, though clinical trial data suggest the combination is generally well-tolerated when appropriate dose titration strategies are employed
The sooner we identify a pattern, the easier it is to correct
Despite similar half-lives, retatrutide (6 days), tirzepatide (5 days), and semaglutide (7 days) all support once-weekly dosing
Clinical studies like the SURPASS trial series compared tirzepatide and semaglutide , and their results helped clarify how dual versus single incretin therapy affects outcomes
Cheng KY, Bao Z, Long Y, et al
If those triggers are still there once Mounjaro is no longer reducing your hunger, old eating patterns can return